Lipitor

• 

  Pfizer, Ranbaxy Win Dismissal of Lawsuit Over Generic Lipitor

  US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail.

• 

  Pfizer, Allergan Combining in $160 Billion Deal to Become Largest Drugmaker

  Pfizer and Allergan will join in a $160 billion deal to create the world's largest drugmaker.

• 

  Pfizer, Ranbaxy Win Dismissal of Lawsuit Over Generic Lipitor

  US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail.

• 

  Ranbaxy recalls some batches of generic Lipitor in latest quality blow

  Ranbaxy recalled tablets of atorvastatin calcium, the generic version of Pfizer Inc's cholesterol fighter Lipitor, after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets, the US Food and Drug Administration (FDA) said on its website.

• Ranbaxy Q1 net profit plunges 90% to Rs 126 crore

  Ranbaxy Laboratories, India's largest drugmaker by sales, reported a 90 per cent drop in first quarter net profit compared to the same year-ago period, when it had exclusive rights to a generic version of cholesterol lowering drug Lipitor in the United States.

• Nomura upgrades Ranbaxy to 'buy' on expectations of better margins

  Global brokerage Nomura has upgraded the stock of drug major Ranbaxy to a buy from neutral, and set its 12-month target price at Rs 475.

• HSBC ups Ranbaxy to 'overweight' on generic Lipitor announcement

  HSBC raised its rating on shares of Ranbaxy Laboratories Ltd to 'overweight' from 'underweight' after the Indian drug-maker said it would resume production of a generic version of cholesterol fighter Lipitor for sale in the United States.

• Ranbaxy to resume generic Lipitor production for US

  Generic drugmaker Ranbaxy Laboratories Ltd said on Friday it will resume production of its version of Pfizer's cholesterol fighter Lipitor for sale in the United States after resolving the issues that led to a November recall.

• Ranbaxy stops production of its generic Lipitor: US drug regulator

  Ranbaxy Laboratories has stopped production of its generic version of cholesterol lowering drug Lipitor until it investigates the issue of potential glass particles in certain lots, the US health regulator has said.

• Ranbaxy down 3% after recall of cholesterol drug from US market

  The recall will temporarily disrupt supplies of the generic Lipitor to the US, Ranbaxy, a unit of Japan's Daiichi Sankyo, said in a statement to the Bombay Stock Exchange today.

• Ranbaxy Q4 net ahead of estimates at Rs 1247 cr, Lipitor boosts margins

  Consolidated sales jumped 55 per cent at Rs 3,700 crore year-on-year. Net soared 310%.

• Pfizer quarterly profit falls 19% on generic Lipitor

  Sales in the US, where Pfizer's patent expired on November 30 for Lipitor, the top-selling drug in history, fell to $5.95 billion, from $7.02 billion.

• Ranbaxy starts generic Lipitor shipments from India

  Ranbaxy has started exports of a copycat version of blockbuster cholesterol drug Lipitor to India.

• Ranbaxy launches generic Lipitor in 4 EU markets

  Group Ranbaxy Laboratories has launched generic copies of Lipitor in four European markets.

• Profit Top 10: Citi raises $1.9 bn in HDFC stake sale, markets fall for third straight day

  If you missed our coverage today, here are the top ten stories.